...
beam-img

Beam Therapeutics Inc, Common Stock

BEAM

GSN

$22.51

+$1.13

(5.29%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.85B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
NM
Volume info-icon
This is the total number of shares traded during the most recent trading day.
413.65K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
1.67M
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.77
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$16.95 L
$49.5 H
$22.51

About Beam Therapeutics Inc, Common Stock

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBEAMSectorS&P500
1-Week Return-10.59%0.73%2.66%
1-Month Return-35.67%-3.99%-1.97%
3-Month Return-12.02%0.86%4.57%
6-Month Return9.09%12.64%24.18%
1-Year Return-30.05%8.01%27.69%
3-Year Return-73.89%18.98%27.46%
5-Year Return13.97%71.41%88.29%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue18.00K24.00K51.84M60.92M377.71M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":13.73,"profit":true},{"date":"2022-12-31","value":16.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue5.41M103.18M16.44M22.58M20.01M[{"date":"2019-12-31","value":5.24,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":15.93,"profit":true},{"date":"2022-12-31","value":21.88,"profit":true},{"date":"2023-12-31","value":19.4,"profit":true}]
Gross Profit(5.39M)(103.16M)35.40M38.34M357.70M[{"date":"2019-12-31","value":-1.51,"profit":false},{"date":"2020-12-31","value":-28.84,"profit":false},{"date":"2021-12-31","value":9.9,"profit":true},{"date":"2022-12-31","value":10.72,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(29938.89%)(429812.50%)68.29%62.94%94.70%[{"date":"2019-12-31","value":-31613.87,"profit":false},{"date":"2020-12-31","value":-453859.13,"profit":false},{"date":"2021-12-31","value":72.11,"profit":true},{"date":"2022-12-31","value":66.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses75.17M132.78M444.31M399.40M534.18M[{"date":"2019-12-31","value":14.07,"profit":true},{"date":"2020-12-31","value":24.86,"profit":true},{"date":"2021-12-31","value":83.18,"profit":true},{"date":"2022-12-31","value":74.77,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(75.15M)(132.76M)(392.46M)(338.48M)(176.49M)[{"date":"2019-12-31","value":-7515400000,"profit":false},{"date":"2020-12-31","value":-13276000000,"profit":false},{"date":"2021-12-31","value":-39246500000,"profit":false},{"date":"2022-12-31","value":-33847900000,"profit":false},{"date":"2023-12-31","value":-17648500000,"profit":false}]
Total Non-Operating Income/Expense(873.00K)(60.26M)21.82M93.60M87.55M[{"date":"2019-12-31","value":-0.93,"profit":false},{"date":"2020-12-31","value":-64.39,"profit":false},{"date":"2021-12-31","value":23.31,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.54,"profit":true}]
Pre-Tax Income(78.33M)(194.59M)(370.64M)(260.18M)(131.16M)[{"date":"2019-12-31","value":-7832600000,"profit":false},{"date":"2020-12-31","value":-19459200000,"profit":false},{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-26017800000,"profit":false},{"date":"2023-12-31","value":-13116100000,"profit":false}]
Income Taxes116.00K61.83M(29.28M)3.41M1.37M[{"date":"2019-12-31","value":0.19,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-47.35,"profit":false},{"date":"2022-12-31","value":5.51,"profit":true},{"date":"2023-12-31","value":2.21,"profit":true}]
Income After Taxes(78.44M)(256.42M)(341.36M)(263.59M)(132.53M)[{"date":"2019-12-31","value":-7844200000,"profit":false},{"date":"2020-12-31","value":-25642400000,"profit":false},{"date":"2021-12-31","value":-34136000000,"profit":false},{"date":"2022-12-31","value":-26358800000,"profit":false},{"date":"2023-12-31","value":-13252700000,"profit":false}]
Income From Continuous Operations(78.33M)(194.59M)(370.64M)(289.09M)(313.67M)[{"date":"2019-12-31","value":-7832600000,"profit":false},{"date":"2020-12-31","value":-19459200000,"profit":false},{"date":"2021-12-31","value":-37063800000,"profit":false},{"date":"2022-12-31","value":-28908800000,"profit":false},{"date":"2023-12-31","value":-31367300000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(78.44M)(256.42M)(341.36M)(263.59M)(132.53M)[{"date":"2019-12-31","value":-7844200000,"profit":false},{"date":"2020-12-31","value":-25642400000,"profit":false},{"date":"2021-12-31","value":-34136000000,"profit":false},{"date":"2022-12-31","value":-26358800000,"profit":false},{"date":"2023-12-31","value":-13252699900,"profit":false}]
EPS (Diluted)(6.36)(4.10)(5.94)(4.13)(1.90)[{"date":"2019-12-31","value":-636,"profit":false},{"date":"2020-12-31","value":-410,"profit":false},{"date":"2021-12-31","value":-594,"profit":false},{"date":"2022-12-31","value":-413,"profit":false},{"date":"2023-12-31","value":-190,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BEAM
Cash Ratio 5.79
Current Ratio 5.89

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BEAM
ROA (LTM) -7.88%
ROE (LTM) -15.46%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BEAM
Debt Ratio Lower is generally better. Negative is bad. 0.33
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.67
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. 1.49

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BEAM
Trailing PE NM
Forward PE NM
P/S (TTM) 5.61
P/B 2.16
Price/FCF 13
EV/R 2.91
EV/Ebitda NM
PEG NM

News

Beam Therapeutics Stock (NASDAQ:BEAM): Investing in Cutting-Edge Gene Editing

CRISPR gene editing technology presents a significant advancement in drug development. This revolutionary tool offers scientists the potential to t…

22 Apr, 2024 a 8:37 pm TipRanks

Is Beam Therapeutics Stock (NASDAQ:BEAM) Too Late to the Game?

Beam Therapeutics (NASDAQ:BEAM) is a gene editing company — one that gets less attention than its peers. Nonetheless, it currently has a $2.7 billi…

30 Mar, 2024 a 7:48 pm TipRanks

Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK

WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK''s Medicines and Healthcare Products Regulatory Agency gave clearance to the company''s clinical trial authorization (CTA) ap…

26 Mar, 2024 a 11:36 am Finanz Nachrichten

Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences | BEAM Stock News

Beam Therapeutics Inc. (BEAM) will participate in upcoming investor conferences to discuss its precision genetic medicines through base editing. The conferences include TD Cowen 44th Annual Health Care Conference, Leerink Partners Global Biopharma Conference, and Barclays Global Healthcare Conference. The webcasts will be available on the company''s website.

28 Feb, 2024 a 11:30 am Stock Titan

FAQs

What is Beam Therapeutics Inc share price today?

Beam Therapeutics Inc (BEAM) share price today is $22.51

Can Indians buy Beam Therapeutics Inc shares?

Yes, Indians can buy shares of Beam Therapeutics Inc (BEAM) on Vested. To buy Beam Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BEAM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Beam Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Beam Therapeutics Inc (BEAM) via the Vested app. You can start investing in Beam Therapeutics Inc (BEAM) with a minimum investment of $1.

How to invest in Beam Therapeutics Inc shares from India?

You can invest in shares of Beam Therapeutics Inc (BEAM) via Vested in three simple steps:

  • Click on Sign Up or Invest in BEAM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Beam Therapeutics Inc shares
What is Beam Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Beam Therapeutics Inc (BEAM) is $49.5. The 52-week low price of Beam Therapeutics Inc (BEAM) is $16.95.

What is Beam Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Beam Therapeutics Inc (BEAM) is NM

What is Beam Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Beam Therapeutics Inc (BEAM) is 2.16

What is Beam Therapeutics Inc dividend yield?

The dividend yield of Beam Therapeutics Inc (BEAM) is 0.00%

What is the Market Cap of Beam Therapeutics Inc?

The market capitalization of Beam Therapeutics Inc (BEAM) is $1.85B

What is Beam Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Beam Therapeutics Inc is BEAM

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top